Pharmaceutical protein production by transgenic chickens: several viewpoints towards the next stage
Protein Expression and Purification · 2026
DOI: 10.1016/j.pep.2026.106900 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Protein Expression and Purification, 2026. Verfasst von Ken-Ichi Nishijima und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan; Avian B…. Hauptthemen laut MEDLINE: Chickens, Animals, Genetically Modified, Recombinant Proteins, Egg Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Bio-oriented Technology Research Advancement Institution, Japan Agency for Medical Research and Development, Japan Science and Technology Agency.
Abstract (Originalsprache)
Several pharmaceuticals produced by transgenic chickens, Kanuma and Epovet, are already in commercial use, which indicates the potential cost competitiveness of this approach as an "animal bioreactor." Since the establishment of reliable cultivation and genetic modification methods for chicken primordial germ cells, the robustness of this system has increased significantly. Moreover, even proteins that might otherwise be deleterious if expressed systemically may be produced when their expression is restricted to the oviduct through the use of tissue-specific promoters. In this review, we discuss several critical issues that must be addressed in order to advance chicken bioreactor systems to the next stage. First, glycosylation profiles should be optimized according to the intended application. Although chickens generally exhibit mammalian-like glycosylation patterns, egg white proteins are known to carry relatively short glycans that lack terminal galactose and sialic acid residues. Therefore, technologies enabling the introduction of appropriate glycan structures need to be developed. Second, the screening process for establishing transgenic lines should be minimized to reduce overall production costs. Recent advances in site-specific genome modification technology are promising in this regard, provided that patent disputes can be resolved. The integration of these emerging strategies into transgenic chicken bioreactor platforms could further enhance their competitiveness as systems for recombinant protein production.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan; Avian Bioscience Research Center, Graduate School of Bioagricultural Sciences…
Förderung
- Bio-oriented Technology Research Advancement Institution
- Japan Agency for Medical Research and Development
- Japan Science and Technology Agency
- Nagoya University
- National Agriculture and Food Research Organization
- Japan Society for the Promotion of Science
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Nishijima, K. I., & Okuzaki, Y. (2026). Pharmaceutical protein production by transgenic chickens: several viewpoints towards the next stage. Protein Expression and Purification. https://doi.org/10.1016/j.pep.2026.106900
Vancouver
Nishijima KI, Okuzaki Y. Pharmaceutical protein production by transgenic chickens: several viewpoints towards the next stage. Protein Expression and Purification. 2026. doi:10.1016/j.pep.2026.106900
BibTeX
@article{Nishijima2026,
author = {Nishijima, Ken-Ichi and Okuzaki, Yuya},
title = {Pharmaceutical protein production by transgenic chickens: several viewpoints towards the next stage},
journal = {Protein Expression and Purification},
year = {2026},
doi = {10.1016/j.pep.2026.106900}
}
EUVIMED